Individualizing decision-making - Resurrecting the doctor-patient relationship in the anemia debate

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Among patients with chronic kidney disease (CKD), erythropoiesis- stimulating agents (ESAs) are approved for avoiding transfusions, a risk that increases when hemoglobin (Hgb) falls to <10 g/dl. Transfusions increase sensitization, prolong the waiting time to and the likelihood of transplantation, and when transplantation is performed worsen graft survival. Accordingly, the risk of transfusion among those expecting transplantation is comparable to that of cardiovascular events. Nonetheless, targeting Hgb to >13 g/dl is associated with increased cardiovascular events. Paradoxically, if this level is achieved mortality is lower. The anemia paradox - higher cardiovascular events when targeting higher Hgb but lower events when patients achieve these targets - appears to be at least partially attributable to a hyporeponse to ESAs. Whether it is the ESAs or conditions that lead to the increased ESA dose that provokes morbidity cannot be answered definitively at present. The lowest ESA dose to achieve the desired level of anemia correction appears to be a safer strategy. In acute illnesses, reducing the dose of ESAs or stopping it altogether may aggravate anemia, but this may be permissible. The rate of rise in Hgb >1 g/dl in any 2-week period is associated with an increase in blood pressure (BP) and poor outcomes. Accordingly, while initiating and maintaining ESA therapy, monitoring BP at home twice daily is warranted. The clinical decision-making process in managing anemia should consider the risks of transfusion; kidney transplant potential; presence of cancer; and the risks of stroke, heart failure, and possibly death. Above all, clinical decision-making should incorporate patient preference.

Original languageEnglish
Pages (from-to)1340-1346
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Hematinics
Anemia
Decision Making
Hemoglobins
Ambulatory Blood Pressure Monitoring
Patient Preference
Chronic Renal Insufficiency
Heart Failure
Stroke
Blood Pressure
Morbidity
Transplants
Kidney
Mortality

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

@article{5988a2c3081246d590f2fb09d9b90dde,
title = "Individualizing decision-making - Resurrecting the doctor-patient relationship in the anemia debate",
abstract = "Among patients with chronic kidney disease (CKD), erythropoiesis- stimulating agents (ESAs) are approved for avoiding transfusions, a risk that increases when hemoglobin (Hgb) falls to <10 g/dl. Transfusions increase sensitization, prolong the waiting time to and the likelihood of transplantation, and when transplantation is performed worsen graft survival. Accordingly, the risk of transfusion among those expecting transplantation is comparable to that of cardiovascular events. Nonetheless, targeting Hgb to >13 g/dl is associated with increased cardiovascular events. Paradoxically, if this level is achieved mortality is lower. The anemia paradox - higher cardiovascular events when targeting higher Hgb but lower events when patients achieve these targets - appears to be at least partially attributable to a hyporeponse to ESAs. Whether it is the ESAs or conditions that lead to the increased ESA dose that provokes morbidity cannot be answered definitively at present. The lowest ESA dose to achieve the desired level of anemia correction appears to be a safer strategy. In acute illnesses, reducing the dose of ESAs or stopping it altogether may aggravate anemia, but this may be permissible. The rate of rise in Hgb >1 g/dl in any 2-week period is associated with an increase in blood pressure (BP) and poor outcomes. Accordingly, while initiating and maintaining ESA therapy, monitoring BP at home twice daily is warranted. The clinical decision-making process in managing anemia should consider the risks of transfusion; kidney transplant potential; presence of cancer; and the risks of stroke, heart failure, and possibly death. Above all, clinical decision-making should incorporate patient preference.",
author = "Rajiv Agarwal",
year = "2010",
month = "7",
day = "1",
doi = "10.2215/CJN.02830310",
language = "English",
volume = "5",
pages = "1340--1346",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Individualizing decision-making - Resurrecting the doctor-patient relationship in the anemia debate

AU - Agarwal, Rajiv

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Among patients with chronic kidney disease (CKD), erythropoiesis- stimulating agents (ESAs) are approved for avoiding transfusions, a risk that increases when hemoglobin (Hgb) falls to <10 g/dl. Transfusions increase sensitization, prolong the waiting time to and the likelihood of transplantation, and when transplantation is performed worsen graft survival. Accordingly, the risk of transfusion among those expecting transplantation is comparable to that of cardiovascular events. Nonetheless, targeting Hgb to >13 g/dl is associated with increased cardiovascular events. Paradoxically, if this level is achieved mortality is lower. The anemia paradox - higher cardiovascular events when targeting higher Hgb but lower events when patients achieve these targets - appears to be at least partially attributable to a hyporeponse to ESAs. Whether it is the ESAs or conditions that lead to the increased ESA dose that provokes morbidity cannot be answered definitively at present. The lowest ESA dose to achieve the desired level of anemia correction appears to be a safer strategy. In acute illnesses, reducing the dose of ESAs or stopping it altogether may aggravate anemia, but this may be permissible. The rate of rise in Hgb >1 g/dl in any 2-week period is associated with an increase in blood pressure (BP) and poor outcomes. Accordingly, while initiating and maintaining ESA therapy, monitoring BP at home twice daily is warranted. The clinical decision-making process in managing anemia should consider the risks of transfusion; kidney transplant potential; presence of cancer; and the risks of stroke, heart failure, and possibly death. Above all, clinical decision-making should incorporate patient preference.

AB - Among patients with chronic kidney disease (CKD), erythropoiesis- stimulating agents (ESAs) are approved for avoiding transfusions, a risk that increases when hemoglobin (Hgb) falls to <10 g/dl. Transfusions increase sensitization, prolong the waiting time to and the likelihood of transplantation, and when transplantation is performed worsen graft survival. Accordingly, the risk of transfusion among those expecting transplantation is comparable to that of cardiovascular events. Nonetheless, targeting Hgb to >13 g/dl is associated with increased cardiovascular events. Paradoxically, if this level is achieved mortality is lower. The anemia paradox - higher cardiovascular events when targeting higher Hgb but lower events when patients achieve these targets - appears to be at least partially attributable to a hyporeponse to ESAs. Whether it is the ESAs or conditions that lead to the increased ESA dose that provokes morbidity cannot be answered definitively at present. The lowest ESA dose to achieve the desired level of anemia correction appears to be a safer strategy. In acute illnesses, reducing the dose of ESAs or stopping it altogether may aggravate anemia, but this may be permissible. The rate of rise in Hgb >1 g/dl in any 2-week period is associated with an increase in blood pressure (BP) and poor outcomes. Accordingly, while initiating and maintaining ESA therapy, monitoring BP at home twice daily is warranted. The clinical decision-making process in managing anemia should consider the risks of transfusion; kidney transplant potential; presence of cancer; and the risks of stroke, heart failure, and possibly death. Above all, clinical decision-making should incorporate patient preference.

UR - http://www.scopus.com/inward/record.url?scp=77954799492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954799492&partnerID=8YFLogxK

U2 - 10.2215/CJN.02830310

DO - 10.2215/CJN.02830310

M3 - Article

C2 - 20448071

AN - SCOPUS:77954799492

VL - 5

SP - 1340

EP - 1346

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 7

ER -